Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
William G. Wierda(University of Maryland, Baltimore), Paolo Ghia(Vita-Salute San Raffaele University), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Bastien Nguyen(Eli Lilly (United States)), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Talha Munir(Leeds Teaching Hospitals NHS Trust), David Lewis(Saint John Regional Hospital), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Donald E. Tsai(University of Pennsylvania), Koji Izutsu(Tokyo National Hospital), Binoj C. Nair(Eli Lilly (United States)), Constantine S. Tam(The Alfred Hospital), Manish Patel(Sarah Cannon), Matthew McKinney(Duke Cancer Institute), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Toby A. Eyre(Oxford University Hospitals NHS Trust), Samuel McNeely(Eli Lilly (United States)), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Paolo Abada(Eli Lilly (United States)), Chan Y. Cheah(The University of Western Australia), Philip A. Thompson(The Royal Melbourne Hospital), John F. Seymour(The Royal Melbourne Hospital), Caleb Ho(Emergency Medicine Foundation), Alvaro J. Alencar(University of Miami), Nirav N. Shah(Medical College of Wisconsin), Hui Liu(Shanghai University), Shuo Ma(Northwestern University), Wojciech Jurczak(Jagiellonian University), Yucai Wang(Mayo Clinic), Amy S. Ruppert(The University of Texas MD Anderson Cancer Center), Narasimha Marella(Loxo Oncology at Lilly (United States)), Chunxiao Wang(Eli Lilly (United States)), Marc Hoffmann(The University of Kansas Cancer Center)
Cited by 37
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k